BTAI - BioXcel Therapeutics Inc

-

$undefined

N/A

(N/A)

BioXcel Therapeutics Inc NasdaqCM:BTAI BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Location: 555 Long Wharf Drive, New Haven, CT, 06511, United States | Website: https://www.bioxceltherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

82.31M

Cash

31.01M

Avg Qtr Burn

-16.59M

Short % of Float

2.41%

Insider Ownership

8.61%

Institutional Own.

11.02%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IGALMI (dexmedetomidine) (BXCL501) Details
Mental health, Bipolar depression, Schizophrenia, Bipolar disease

Approved

Quarterly sales

BXCL501 Details
Bipolar depression, Bipolar disease, Mental health, Schizophrenia, Agitation

Phase 3

Data readout

BXCL501 Details
Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease

Phase 3

Initiation

BXCL701 + KEYTRUDA Details
Neuroendocrine prostate cancer, Castration-resistant prostate cancer

Phase 2b

Update

BXCL701 + KEYTRUDA Details
Solid tumor/s, Cancer, Pancreatic cancer

Phase 2

Data readout

BXCL501 + Duloxetine Details
Major depressive disorder

Phase 2

Initiation

BXCL501 Details
Mental health, Acute stress disorder

Phase 2a

Initiation

BXCL501 Details
Opioid use disorder

Phase 1

Update

BXCL501 Details
Mental health, Delirium, Agitation

Failed

Discontinued